Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
In Vitro DiagnosticsCancerCancer Diagnostic

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1223491

Cover Image

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1223491

Europe Uterine Cancer Diagnostics Market - Industry Trends and Forecast to 2030

PUBLISHED:
PAGES: 476 Pages
DELIVERY TIME: Inquiry
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License) - Printable/Downloadable
USD 3500
PDF (Enterprise License) - Printable/Downloadable
USD 4200

Add to Cart

Description

Table of Contents

List of Tables

Europe uterine cancer diagnostics market is projected to register a CAGR of 10.5% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

Europe Uterine Cancer Diagnostics Market, By Diagnostic Type (Instrument Based and Procedure Based), Type (Endometrial Cancer and Uterine Sarcoma), Age Group (<30, 31-40, 41-50, 51-60 And >60), End User (Hospitals, Diagnostic Centres, Cancer Research Centre, Ambulatory Surgical Centres, Specialized Clinics, and Others), Distribution Channel (Direct Tender, Third Party Distributors, and Others), Country (Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the Europe uterine cancer diagnostics market are:

Increasing uterine cancer patients among the women population

Rise in technological advancement for uterine cancer diagnosis

Market Players

Some of the key market players operating in the Europe uterine cancer diagnostics market are:

F-Hoffmann La Roche Ltd.

Siemens Healthcare Private Limited

ESAOTE SPA

Olympus Corporation

Integra LifeSciences

KARL STORZ SE & Co. KG

Stryker

General Electric Company

FUJIFILM Corporation

Koninklijke Philips N.V.

B. Braun SE

Arquer Diagnostics Ltd

Surtex Instruments Limited

GRAIL

Show more

TABLE OF CONTENTS

1 INTRODUCTION 118

  • 1.1 OBJECTIVES OF THE STUDY 118
  • 1.2 MARKET DEFINITION 118
  • 1.3 OVERVIEW OF THE EUROPE UTERINE CANCER DIAGNOSTIC MARKET 118
  • 1.4 CURRENCY AND PRICING 120
  • 1.5 LIMITATIONS 120
  • 1.6 MARKETS COVERED 120

2 MARKET SEGMENTATION 128

  • 2.1 MARKETS COVERED 128
  • 2.2 GEOGRAPHICAL SCOPE 129
  • 2.3 YEARS CONSIDERED FOR THE STUDY 130
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 131
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 134
  • 2.6 MULTIVARIATE MODELLING 135
  • 2.7 MARKET APPLICATION COVERAGE GRID 136
  • 2.8 INSTRUMENT BASED LIFELINE CURVE 137
  • 2.9 DBMR MARKET POSITION GRID 138
  • 2.10 VENDOR SHARE ANALYSIS 140
  • 2.11 SECONDARY SOURCES 141
  • 2.12 ASSUMPTIONS 141

3 EXECUTIVE SUMMARY 142

4 PREMIUM INSIGHTS 145

  • 4.1 PESTEL ANALYSIS 146
  • 4.2 PORTER'S FIVE FORCES 147
  • 4.3 PATENT ANALYSIS OF EUROPE UTERINE CANCER DIAGNOSTICS MARKET 148
  • 4.4 REIMBURSEMENT SCENARIO 149
  • 4.5 INDUSTRY INSIGHTS: 150
  • 4.6 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 150
  • 4.7 PRICING STRATEGIES 150
  • 4.8 CONCLUSION 151
  • 4.9 PREVALENCE, INCIDENCE, AND MORTALITY RATE OF UTERINE CANCER 152
  • 4.10 COST OF UTERINE CANCER PROCEDURE 154

5 REGULATORY FRAMEWORK 155

6 MARKET OVERVIEW 157

  • 6.1 DRIVERS 159
    • 6.1.1 TECHNOLOGICAL ADVANCEMENTS IN UTERINE CANCER DIAGNOSTICS 159
    • 6.1.2 RISING DEMAND FOR MINIMALLY INVASIVE ADVANCED SCREENING TECHNIQUES 159
    • 6.1.3 RISING AWARENESS TOWARDS UTERINE CANCER 160
    • 6.1.4 RISING IMPORTANCE OF WOMEN'S HEALTH 160
  • 6.2 RESTRAINTS 161
    • 6.2.1 HIGH RISK COMPLICATIONS DURING DIAGNOSTIC TESTS 161
    • 6.2.2 LACK OF SKILLED PROFESSIONALS FOR PROPER DIAGNOSIS OF UTERINE CANCER 161
  • 6.3 OPPORTUNITIES 162
    • 6.3.1 INCREASING PREVALENCE OF UTERINE CANCER 162
    • 6.3.2 RISE IN ADOPTION OF SEDENTARY LIFESTYLE 162
    • 6.3.3 GROWTH IN MENSTRUAL COMPLICATIONS 163
  • 6.4 CHALLENGES 163
    • 6.4.1 LACK OF DIAGNOSTIC INFRASTRUCTURE 163
    • 6.4.2 HIGH COST OF IMAGING SYSTEMS 164

7 EUROPE UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE 165

  • 7.1 OVERVIEW 166
  • 7.2 INSTRUMENT-BASED 169
    • 7.2.1 ULTRASOUND SCANNING 170
      • 7.2.1.1 SYSTEMS 170
      • 7.2.1.2 ABDOMINAL ULTRASOUND SCANNING 171
      • 7.2.1.3 TRANSVAGINAL ULTRASOUND SCANNING 171
      • 7.2.1.4 ACCESSORIES 171
    • 7.2.2 IMAGING DEVICES 171
      • 7.2.2.1 CT/PET (POSITRON EMISSION TOMOGRAPHY) SCAN 172
      • 7.2.2.2 MAGNETIC RESONANCE IMAGING (MRI) 172
      • 7.2.2.3 COMPUTED TOMOGRAPHY (CT) SCAN 172
      • 7.2.2.4 OTHERS 172
    • 7.2.3 TESTS 173
      • 7.2.3.1 BLOOD TESTS 173
        • 7.2.3.1.1 COMPLETE BLOOD COUNT 173
        • 7.2.3.1.2 CA125 MARKER BLOOD TEST 173
      • 7.2.3.2 URINE TESTS 174
      • 7.2.3.3 OTHER TESTS 174
    • 7.2.4 OTHERS 174
  • 7.3 PROCEDURE BASED 174
    • 7.3.1 ENDOMETRIAL BIOPSY 175
    • 7.3.2 HYSTEROSCOPY 175
    • 7.3.3 DILATION & CURETTAGE 175
    • 7.3.4 CYSTOSCOPY 175
    • 7.3.5 PROCTOSCOPY 176
    • 7.3.6 OTHERS 176

8 EUROPE UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE 177

  • 8.1 OVERVIEW 178
  • 8.2 ENDOMETRIAL CANCER 181
    • 8.2.1 SEROUS ADENOCARCINOMA 182
      • 8.2.1.1 INSTRUMENT-BASED 182
        • 8.2.1.1.1 ULTRASOUND SCANNING 183
        • 8.2.1.1.2 IMAGING DEVICES 183
        • 8.2.1.1.3 TESTS 183
        • 8.2.1.1.4 OTHERS 183
      • 8.2.1.2 PROCEDURE-BASED 184
        • 8.2.1.2.1 ENDOMETRIAL BIOPSY 184
        • 8.2.1.2.2 HYSTEROSCOPY 184
        • 8.2.1.2.3 DILATION & CURETTAGE 184
        • 8.2.1.2.4 CYSTOSCOPY 184
        • 8.2.1.2.5 PROCTOSCOPY 184
        • 8.2.1.2.6 OTHERS 185
    • 8.2.2 ADENOSQUAMOUS CARCINOMA 185
      • 8.2.2.1 INSTRUMENT-BASED 185
        • 8.2.2.1.1 ULTRASOUND SCANNING 185
        • 8.2.2.1.2 IMAGING DEVICES 186
        • 8.2.2.1.3 TESTS 186
        • 8.2.2.1.4 OTHERS 186
      • 8.2.2.2 PROCEDURE-BASED 186
        • 8.2.2.2.1 ENDOMETRIAL BIOPSY 186
        • 8.2.2.2.2 HYSTEROSCOPY 186
        • 8.2.2.2.3 DILATION & CURETTAGE 187
        • 8.2.2.2.4 CYSTOSCOPY 187
        • 8.2.2.2.5 PROCTOSCOPY 187
        • 8.2.2.2.6 OTHERS 187
    • 8.2.3 UTERINE CARCINOSARCOMA 187
      • 8.2.3.1 INSTRUMENT-BASED 187
        • 8.2.3.1.1 ULTRASOUND SCANNING 188
        • 8.2.3.1.2 IMAGING DEVICES 188
        • 8.2.3.1.3 TESTS 188
        • 8.2.3.1.4 OTHERS 188
      • 8.2.3.2 PROCEDURE-BASED 189
        • 8.2.3.2.1 ENDOMETRIAL BIOPSY 189
        • 8.2.3.2.2 HYSTEROSCOPY 189
        • 8.2.3.2.3 DILATION & CURETTAGE 189
        • 8.2.3.2.4 CYSTOSCOPY 189
        • 8.2.3.2.5 PROCTOSCOPY 189
        • 8.2.3.2.6 OTHERS 190
    • 8.2.4 PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM 190
      • 8.2.4.1 INSTRUMENT-BASED 190
        • 8.2.4.1.1 ULTRASOUND SCANNING 190
        • 8.2.4.1.2 IMAGING DEVICES 191
        • 8.2.4.1.3 TESTS 191
        • 8.2.4.1.4 OTHERS 191
      • 8.2.4.2 PROCEDURE-BASED 191
        • 8.2.4.2.1 ENDOMETRIAL BIOPSY 191
        • 8.2.4.2.2 HYSTEROSCOPY 191
        • 8.2.4.2.3 DILATION & CURETTAGE 192
        • 8.2.4.2.4 CYSTOSCOPY 192
        • 8.2.4.2.5 PROCTOSCOPY 192
        • 8.2.4.2.6 OTHERS 192
  • 8.3 UTERINE SARCOMA 192
    • 8.3.1 LEIOMYOSARCOMA 193
      • 8.3.1.1 INSTRUMENT-BASED 193
        • 8.3.1.1.1 ULTRASOUND SCANNING 194
        • 8.3.1.1.2 IMAGING DEVICES 194
        • 8.3.1.1.3 TESTS 194
        • 8.3.1.1.4 OTHERS 194
      • 8.3.1.2 PROCEDURE-BASED 195
        • 8.3.1.2.1 ENDOMETRIAL BIOPSY 195
        • 8.3.1.2.2 HYSTEROSCOPY 195
        • 8.3.1.2.3 DILATION & CURETTAGE 195
        • 8.3.1.2.4 CYSTOSCOPY 195
        • 8.3.1.2.5 PROCTOSCOPY 195
        • 8.3.1.2.6 OTHERS 196
    • 8.3.2 ENDOMETRIAL STROMAL SARCOMA 196
      • 8.3.2.1 INSTRUMENT-BASED 196
        • 8.3.2.1.1 ULTRASOUND SCANNING 196
        • 8.3.2.1.2 IMAGING DEVICES 197
        • 8.3.2.1.3 TESTS 197
        • 8.3.2.1.4 OTHERS 197
      • 8.3.2.2 PROCEDURE-BASED 197
        • 8.3.2.2.1 ENDOMETRIAL BIOPSY 197
        • 8.3.2.2.2 HYSTEROSCOPY 197
        • 8.3.2.2.3 DILATION & CURETTAGE 198
        • 8.3.2.2.4 CYSTOSCOPY 198
        • 8.3.2.2.5 PROCTOSCOPY 198
        • 8.3.2.2.6 OTHERS 198
    • 8.3.3 UNDIFFERENTIATED SARCOMA 198
      • 8.3.3.1 INSTRUMENT-BASED 199
        • 8.3.3.1.1 ULTRASOUND SCANNING 199
        • 8.3.3.1.2 IMAGING DEVICES 199
        • 8.3.3.1.3 TESTS 199
        • 8.3.3.1.4 OTHERS 199
      • 8.3.3.2 PROCEDURE-BASED 200
        • 8.3.3.2.1 ENDOMETRIAL BIOPSY 200
        • 8.3.3.2.2 HYSTEROSCOPY 200
        • 8.3.3.2.3 DILATION & CURETTAGE 200
        • 8.3.3.2.4 CYSTOSCOPY 200
        • 8.3.3.2.5 PROCTOSCOPY 201
        • 8.3.3.2.6 OTHERS 201

9 EUROPE UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP 202

  • 9.1 OVERVIEW 203
  • 9.2 >60 YEARS 206
  • 9.3 51-60 YEARS 207
  • 9.4 41-50 YEARS 208
  • 9.5 31-40 YEARS 209
  • 9.6 <30 YEARS 210

10 EUROPE UTERINE CANCER DIAGNOSTICS MARKET, BY END USER 211

  • 10.1 OVERVIEW 212
  • 10.2 HOSPITALS 215
  • 10.3 DIAGNOSTIC CENTERS 216
  • 10.4 CANCER RESEARCH CENTERS 217
  • 10.5 AMBULATORY SURGICAL CENTERS 218
  • 10.6 SPECIALIZED CLINICS 219
  • 10.7 OTHERS 220

11 EUROPE UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 221

  • 11.1 OVERVIEW 222
  • 11.2 DIRECT TENDER 225
  • 11.3 THIRD PARTY DISTRIBUTORS 226
  • 11.4 OTHERS 227

12 EUROPE UTERINE CANCER DIAGNOSTICS MARKET, BY REGION 228

  • 12.1 EUROPE 229
    • 12.1.1 GERMANY 245
    • 12.1.2 FRANCE 256
    • 12.1.3 UNITED KINGDOM 268
    • 12.1.4 ITALY 281
    • 12.1.5 SPAIN 293
    • 12.1.6 RUSSIA 304
    • 12.1.7 NETHERLANDS 317
    • 12.1.8 POLAND 330
    • 12.1.9 SWITZERLAND 343
    • 12.1.10 BELGIUM 356
    • 12.1.11 SWEDEN 369
    • 12.1.12 NORWAY 382
    • 12.1.13 DENMARK 395
    • 12.1.14 FINLAND 408
    • 12.1.15 TURKEY 421
    • 12.1.16 REST OF EUROPE 434

13 EUROPE UTERINE CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 435

  • 13.1 COMPANY SHARE ANALYSIS: EUROPE 435

14 SWOT ANALYSIS 436

15 COMPANY PROFILE 437

  • 15.1 KONINKLIJKE PHILIPS N.V. 437
    • 15.1.1 COMPANY SNAPSHOT 437
    • 15.1.2 REVENUE ANALYSIS 437
    • 15.1.3 COMPANY SHARE ANALYSIS 438
    • 15.1.4 PRODUCT PORTFOLIO 438
    • 15.1.5 RECENT DEVELOPMENTS 438
  • 15.2 CANON MEDICAL SYSTEMS ANZ PTY LIMITED. 440
    • 15.2.1 COMPANY SNAPSHOT 440
    • 15.2.2 COMPANY SHARE ANALYSIS 440
    • 15.2.3 PRODUCT PORTFOLIO 441
    • 15.2.4 RECENT DEVELOPMENTS 441
  • 15.3 GENERAL ELECTRIC COMPANY 442
    • 15.3.1 COMPANY SNAPSHOT 442
    • 15.3.2 REVENUE ANALYSIS 442
    • 15.3.3 COMPANY SHARE ANALYSIS 443
    • 15.3.4 PRODUCT PORTFOLIO 443
    • 15.3.5 RECENT DEVELOPMENTS 443
  • 15.4 SIEMENS HEALTHCARE GMBH 445
    • 15.4.1 COMPANY SNAPSHOT 445
    • 15.4.2 REVENUE ANALYSIS 445
    • 15.4.3 COMPANY SHARE ANALYSIS 446
    • 15.4.4 PRODUCT PORTFOLIO 446
    • 15.4.5 RECENT DEVELOPMENTS 446
  • 15.5 FUJIFILM CORPORATION 447
    • 15.5.1 COMPANY SNAPSHOT 447
    • 15.5.2 REVENUE ANALYSIS 447
    • 15.5.3 COMPANY SHARE ANALYSIS 448
    • 15.5.4 PRODUCT PORTFOLIO 448
    • 15.5.5 RECENT DEVELOPMENTS 448
  • 15.6 AED.MD 450
    • 15.6.1 COMPANY SNAPSHOT 450
    • 15.6.2 PRODUCT PORTFOLIO 450
    • 15.6.3 RECENT DEVELOPMENTS 450
  • 15.7 ARQUER DIAGNOSTICS LTD 451
    • 15.7.1 COMPANY SNAPSHOT 451
    • 15.7.2 PRODUCT PORTFOLIO 451
    • 15.7.3 RECENT DEVELOPMENTS 451
Show more
  • 15.8 B. BRAUN SE 452
    • 15.8.1 COMPANY SNAPSHOT 452
    • 15.8.2 PRODUCT PORTFOLIO 452
    • 15.8.3 RECENT DEVELOPMENTS 452
  • 15.9 ESAOTE SPA 453
    • 15.9.1 COMPANY SNAPSHOT 453
    • 15.9.2 PRODUCT PORTFOLIO 453
    • 15.9.3 RECENT DEVELOPMENTS 453
  • 15.10 F. HOFFMANN-LA ROCHE LTD 455
    • 15.10.1 COMPANY SNAPSHOT 455
    • 15.10.2 REVENUE ANALYSIS 455
    • 15.10.3 PRODUCT PORTFOLIO 456
    • 15.10.4 RECENT DEVELOPMENTS 456
  • 15.11 GRAIL 457
    • 15.11.1 COMPANY SNAPSHOT 457
    • 15.11.2 PRODUCT PORTFOLIO 457
    • 15.11.3 RECENT DEVELOPMENTS 457
  • 15.12 GUZIP BIOMARKERS CORPORATION 459
    • 15.12.1 COMPANY SNAPSHOT 459
    • 15.12.2 PRODUCT PORTFOLIO 459
    • 15.12.3 RECENT DEVELOPMENTS 459
  • 15.13 INTEGRA LIFESCIENCES 460
    • 15.13.1 COMPANY SNAPSHOT 460
    • 15.13.2 REVENUE ANALYSIS 460
    • 15.13.3 PRODUCT PORTFOLIO 461
    • 15.13.4 RECENT DEVELOPMENTS 461
  • 15.14 JALAL SURGICAL 462
    • 15.14.1 COMPANY SNAPSHOT 462
    • 15.14.2 PRODUCT PORTFOLIO 462
    • 15.14.3 RECENT DEVELOPMENTS 462
  • 15.15 KARL STORZ SE & CO. KG 463
    • 15.15.1 COMPANY SNAPSHOT 463
    • 15.15.2 PRODUCT PORTFOLIO 463
    • 15.15.3 RECENT DEVELOPMENTS 464
  • 15.16 MEDTRONIC 465
    • 15.16.1 COMPANY SNAPSHOT 465
    • 15.16.2 REVENUE ANALYSIS 465
    • 15.16.3 PRODUCT PORTFOLIO 466
    • 15.16.4 RECENT DEVELOPMENTS 466
  • 15.17 NARANG MEDICAL LIMITED 467
    • 15.17.1 COMPANY SNAPSHOT 467
    • 15.17.2 PRODUCT PORTFOLIO 467
    • 15.17.3 RECENT DEVELOPMENTS 467
  • 15.18 OLYMPUS CORPORATION 468
    • 15.18.1 COMPANY SNAPSHOT 468
    • 15.18.2 REVENUE ANALYSIS 468
    • 15.18.3 PRODUCT PORTFOLIO 469
    • 15.18.4 RECENT DEVELOPMENTS 469
  • 15.19 STRYKER 470
    • 15.19.1 COMPANY SNAPSHOT 470
    • 15.19.2 REVENUE ANALYSIS 470
    • 15.19.3 PRODUCT PORTFOLIO 471
    • 15.19.4 RECENT DEVELOPMENTS 471
  • 15.20 SURTEX INSTRUMENTS LIMITED. 472
    • 15.20.1 COMPANY SNAPSHOT 472
    • 15.20.2 PRODUCT PORTFOLIO 472
    • 15.20.3 RECENT DEVELOPMENTS 472

16 QUESTIONNAIRE 473

17 RELATED REPORTS 476

LIST OF TABLES

  • TABLE 1 EUROPE RATE OF ENDOMETRIAL CANCER (2020) 86
  • TABLE 2 U.S. (2022) 86
  • TABLE 3 U.K. (2019) 86
  • TABLE 4 GERMANY RATE OF ENDOMETRIAL CANCER (2019) 86
  • TABLE 5 POLAND RATE OF ENDOMETRIAL CANCER (2020) 86
  • TABLE 6 SINGAPORE (2020) 86
  • TABLE 7 JAPAN (2022) 86
  • TABLE 8 INDIA (2020) 87
  • TABLE 9 AUSTRALIA (2022) 87
  • TABLE 10 BRAZIL RATE OF ENDOMETRIAL CANCER (2018) 87
  • TABLE 11 ARGENTINA (2020) 87
  • TABLE 12 UAE (2020) 87
  • TABLE 13 EUROPE UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 102
  • TABLE 14 EUROPE INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 103
  • TABLE 15 EUROPE INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 103
  • TABLE 16 EUROPE ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 104
  • TABLE 17 EUROPE ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 104
  • TABLE 18 EUROPE SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 104
  • TABLE 19 EUROPE SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 105
  • TABLE 20 EUROPE IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 105
  • TABLE 21 EUROPE IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 106
  • TABLE 22 EUROPE TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 107
  • TABLE 23 EUROPE BLOOD TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 107
  • TABLE 24 EUROPE PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 108
  • TABLE 25 EUROPE PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 109
  • TABLE 26 EUROPE PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 109
  • TABLE 27 EUROPE UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 114
  • TABLE 28 EUROPE ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 115
  • TABLE 29 EUROPE ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 116
  • TABLE 30 EUROPE SEROUS ADENOCARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 116
  • TABLE 31 EUROPE INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 117
  • TABLE 32 EUROPE PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 118
  • TABLE 33 EUROPE ADENOSQUAMOUS CARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 119
  • TABLE 34 EUROPE INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 119
  • TABLE 35 EUROPE PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 120
  • TABLE 36 EUROPE UTERINE CARCINOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 121
  • TABLE 37 EUROPE INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 122
  • TABLE 38 EUROPE PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 123
  • TABLE 39 EUROPE PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 124
  • TABLE 40 EUROPE INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 124
  • TABLE 41 EUROPE PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 125
  • TABLE 42 EUROPE UTERINE SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 126
  • TABLE 43 EUROPE UTERINE SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 127
  • TABLE 44 EUROPE LEIOMYOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 127
  • TABLE 45 EUROPE INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 128
  • TABLE 46 EUROPE PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 129
  • TABLE 47 EUROPE ENDOMETRIAL STROMAL SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 130
  • TABLE 48 EUROPE INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 130
  • TABLE 49 EUROPE PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 131
  • TABLE 50 EUROPE UNDIFFERENTIATED SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 132
  • TABLE 51 EUROPE INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 133
  • TABLE 52 EUROPE PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 134
  • TABLE 53 EUROPE UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 139
  • TABLE 54 EUROPE >60 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 140
  • TABLE 55 EUROPE 51-60 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 141
  • TABLE 56 EUROPE 41-50 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 142
  • TABLE 57 EUROPE 31-40 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 143
  • TABLE 58 EUROPE <30 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 144
  • TABLE 59 EUROPE UTERINE CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 148
  • TABLE 60 EUROPE HOSPITALS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 149
  • TABLE 61 EUROPE DIAGNOSTIC CENTERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 150
  • TABLE 62 EUROPE CANCER RESEARCH CENTERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 151
  • TABLE 63 EUROPE AMBULATORY SURGICAL CENTERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 152
  • TABLE 64 EUROPE SPECIALIZED CLINICS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 153
  • TABLE 65 EUROPE OTHERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 154
  • TABLE 66 EUROPE UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 158
  • TABLE 67 EUROPE DIRECT TENDER IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 159
  • TABLE 68 EUROPE THIRD PARTY DISTRIBUTORS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 160
  • TABLE 69 EUROPE OTHERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 161
  • TABLE 70 EUROPE UTERINE CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 167
  • TABLE 71 EUROPE UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 167
  • TABLE 72 EUROPE INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 167
  • TABLE 73 EUROPE ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 168
  • TABLE 74 EUROPE ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 168
  • TABLE 75 EUROPE ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 168
  • TABLE 76 EUROPE SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 168
  • TABLE 77 EUROPE SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME) 168
  • TABLE 78 EUROPE SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 169
  • TABLE 79 EUROPE IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 169
  • TABLE 80 EUROPE IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 169
  • TABLE 81 EUROPE IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 169
  • TABLE 82 EUROPE TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 170
  • TABLE 83 EUROPE BLOOD TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 170
  • TABLE 84 EUROPE PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 170
  • TABLE 85 EUROPE PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME) 170
  • TABLE 86 EUROPE PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 171
  • TABLE 87 EUROPE UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 171
  • TABLE 88 EUROPE ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 171
  • TABLE 89 EUROPE SEROUS ADENOCARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 171
  • TABLE 90 EUROPE INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 172
  • TABLE 91 EUROPE PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 172
  • TABLE 92 EUROPE ADENOSQUAMOUS CARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 172
  • TABLE 93 EUROPE INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 172
  • TABLE 94 EUROPE PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 173
  • TABLE 95 EUROPE UTERINE CARCINOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 173
  • TABLE 96 EUROPE INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 173
  • TABLE 97 EUROPE PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 173
  • TABLE 98 EUROPE PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 174
  • TABLE 99 EUROPE INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 174
  • TABLE 100 EUROPE PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 174
  • TABLE 101 EUROPE UTERINE SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 175
  • TABLE 102 EUROPE LEIOMYOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 175
  • TABLE 103 EUROPE INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 175
  • TABLE 104 EUROPE PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 175
  • TABLE 105 EUROPE ENDOMETRIAL STROMAL SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 176
  • TABLE 106 EUROPE INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 176
  • TABLE 107 EUROPE PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 176
  • TABLE 108 EUROPE UNDIFFERENTIATED SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 176
  • TABLE 109 EUROPE INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 177
  • TABLE 110 EUROPE PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 177
  • TABLE 111 EUROPE UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 177
  • TABLE 112 EUROPE UTERINE CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 178
  • TABLE 113 EUROPE UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 178
  • TABLE 114 GERMANY UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 179
  • TABLE 115 GERMANY INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 179
  • TABLE 116 GERMANY ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 179
  • TABLE 117 GERMANY ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 179
  • TABLE 118 GERMANY ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 180
  • TABLE 119 GERMANY SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 180
  • TABLE 120 GERMANY SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME) 180
  • TABLE 121 GERMANY SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 180
  • TABLE 122 GERMANY IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 180
  • TABLE 123 GERMANY IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 181
  • TABLE 124 GERMANY IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 181
  • TABLE 125 GERMANY TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 181
  • TABLE 126 GERMANY BLOOD TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 181
  • TABLE 127 GERMANY PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 182
  • TABLE 128 GERMANY PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME) 182
  • TABLE 129 GERMANY PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 182
  • TABLE 130 GERMANY UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 182
  • TABLE 131 GERMANY ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 183
  • TABLE 132 GERMANY SEROUS ADENOCARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 183
  • TABLE 133 GERMANY INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 183
  • TABLE 134 GERMANY PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 183
  • TABLE 135 GERMANY ADENOSQUAMOUS CARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 184
  • TABLE 136 GERMANY INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 184
  • TABLE 137 GERMANY PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 184
  • TABLE 138 GERMANY UTERINE CARCINOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 184
  • TABLE 139 GERMANY INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 185
  • TABLE 140 GERMANY PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 185
  • TABLE 141 GERMANY PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 185
  • TABLE 142 GERMANY INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 185
  • TABLE 143 GERMANY PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 186
  • TABLE 144 GERMANY UTERINE SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 186
  • TABLE 145 GERMANY LEIOMYOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 186
  • TABLE 146 GERMANY INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 186
  • TABLE 147 GERMANY PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 187
  • TABLE 148 GERMANY ENDOMETRIAL STROMAL SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 187
  • TABLE 149 GERMANY INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 187
  • TABLE 150 GERMANY PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 188
  • TABLE 151 GERMANY UNDIFFERENTIATED SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 188
  • TABLE 152 GERMANY INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 188
  • TABLE 153 GERMANY PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 188
  • TABLE 154 GERMANY UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 189
  • TABLE 155 GERMANY UTERINE CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 189
  • TABLE 156 GERMANY UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 189
  • TABLE 157 FRANCE UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 190

LIST OF FIGURES

  • FIGURE 1 EUROPE UTERINE CANCER DIAGNOSTIC MARKET: SEGMENTATION 61
  • FIGURE 2 EUROPE UTERINE CANCER DIAGNOSTIC MARKET: DATA TRIANGULATION 64
  • FIGURE 3 EUROPE UTERINE CANCER DIAGNOSTIC MARKET: DROC ANALYSIS 65
  • FIGURE 4 EUROPE UTERINE CANCER DIAGNOSTIC MARKET: EUROPE VS REGIONAL MARKET ANALYSIS 66
  • FIGURE 5 EUROPE UTERINE CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS 66
  • FIGURE 6 EUROPE UTERINE CANCER DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS 67
  • FIGURE 7 EUROPE UTERINE CANCER DIAGNOSTIC MARKET: MARKET APPLICATION COVERAGE GRID 69
  • FIGURE 8 EUROPE UTERINE CANCER DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID 71
  • FIGURE 9 EUROPE UTERINE CANCER DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS 73
  • FIGURE 10 EUROPE UTERINE CANCER DIAGNOSTIC MARKET: SEGMENTATION 77
  • FIGURE 11 GROWING AWARENESS OF UTERINE CANCER AND INCREASING HEALTHCARE EXPENDITURE IS EXPECTED TO DRIVE THE GROWTH OF THE EUROPE UTERINE CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030 78
  • FIGURE 12 INSTRUMENT BASED SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE UTERINE CANCER DIAGNOSTIC MARKET IN 2023 & 2030 78
  • FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE UTERINE CANCER DIAGNOSTICS MARKET 91
  • FIGURE 14 EUROPE UTERINE CANCER DIAGNOSTICS MARKET : BY DIAGNOSTIC TYPE, 2022 99
  • FIGURE 15 EUROPE UTERINE CANCER DIAGNOSTICS MARKET : BY DIAGNOSTIC TYPE, 2023-2030 (USD MILLION) 100
  • FIGURE 16 EUROPE UTERINE CANCER DIAGNOSTICS MARKET : BY DIAGNOSTIC TYPE, CAGR (2023-2030) 100
  • FIGURE 17 EUROPE UTERINE CANCER DIAGNOSTICS MARKET : BY DIAGNOSTIC TYPE, LIFELINE CURVE 101
  • FIGURE 18 EUROPE UTERINE CANCER DIAGNOSTICS MARKET: BY TYPE, 2022 111
  • FIGURE 19 EUROPE UTERINE CANCER DIAGNOSTICS MARKET: BY TYPE, 2023-2030 (USD MILLION) 112
  • FIGURE 20 EUROPE UTERINE CANCER DIAGNOSTICS MARKET: BY TYPE, CAGR (2023-2030) 112
  • FIGURE 21 EUROPE UTERINE CANCER DIAGNOSTICS MARKET: BY TYPE, LIFELINE CURVE 113
  • FIGURE 22 EUROPE UTERINE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2022 136
  • FIGURE 23 EUROPE UTERINE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION) 137
  • FIGURE 24 EUROPE UTERINE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030) 137
  • FIGURE 25 EUROPE UTERINE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE 138
  • FIGURE 26 EUROPE UTERINE CANCER DIAGNOSTICS MARKET : BY END USER, 2022 145
  • FIGURE 27 EUROPE UTERINE CANCER DIAGNOSTICS MARKET : BY END USER, 2023-2030 (USD MILLION) 146
  • FIGURE 28 EUROPE UTERINE CANCER DIAGNOSTICS MARKET : BY END USER, CAGR (2023-2030) 146
  • FIGURE 29 EUROPE UTERINE CANCER DIAGNOSTICS MARKET : BY END USER, LIFELINE CURVE 147
  • FIGURE 30 EUROPE UTERINE CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2022 155
  • FIGURE 31 EUROPE UTERINE CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 156
  • FIGURE 32 EUROPE UTERINE CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 156
  • FIGURE 33 EUROPE UTERINE CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE 157
  • FIGURE 34 EUROPE UTERINE CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 163
  • FIGURE 35 EUROPE UTERINE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 164
  • FIGURE 36 EUROPE UTERINE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 164
  • FIGURE 37 EUROPE UTERINE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 165
  • FIGURE 38 EUROPE UTERINE CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE (2023-2030) 165
  • FIGURE 39 EUROPE UTERINE CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 368
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!